- Home
- SKM vs ROIV Comparison
SKM vs ROIV Comparison
Compare SKM & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKM
- ROIV
- Stock Information
- Founded
- SKM 1984
- ROIV 2014
- Country
- SKM South Korea
- ROIV United Kingdom
- Employees
- SKM N/A
- ROIV N/A
- Industry
- SKM Telecommunications Equipment
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- SKM Telecommunications
- ROIV Health Care
- Exchange
- SKM Nasdaq
- ROIV Nasdaq
- Market Cap
- SKM N/A
- ROIV 7.8B
- IPO Year
- SKM 1996
- ROIV N/A
- Fundamental
- Price
- SKM $23.58
- ROIV $10.99
- Analyst Decision
- SKM Hold
- ROIV Buy
- Analyst Count
- SKM 1
- ROIV 4
- Target Price
- SKM N/A
- ROIV $17.50
- AVG Volume (30 Days)
- SKM 555.0K
- ROIV 7.3M
- Earning Date
- SKM 08-05-2025
- ROIV 08-07-2025
- Dividend Yield
- SKM 3.60%
- ROIV N/A
- EPS Growth
- SKM 10.48
- ROIV N/A
- EPS
- SKM 3.95
- ROIV N/A
- Revenue
- SKM $12,191,932,706.00
- ROIV $29,053,000.00
- Revenue This Year
- SKM $1.65
- ROIV $2.64
- Revenue Next Year
- SKM $1.59
- ROIV $378.09
- P/E Ratio
- SKM $10.09
- ROIV N/A
- Revenue Growth
- SKM 1.21
- ROIV N/A
- 52 Week Low
- SKM $19.84
- ROIV $8.73
- 52 Week High
- SKM $24.58
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- SKM 70.03
- ROIV 44.75
- Support Level
- SKM $23.40
- ROIV $10.83
- Resistance Level
- SKM $23.80
- ROIV $11.82
- Average True Range (ATR)
- SKM 0.25
- ROIV 0.32
- MACD
- SKM 0.12
- ROIV -0.07
- Stochastic Oscillator
- SKM 88.72
- ROIV 16.24
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.